Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $245.51 --0%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VFS, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VFS, More
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
